Important: Therapy notes
MHRA advice: Terlipressin: new recommendations to reduce risks of respiratory failure and septic shock in patients with type 1 hepatorenal syndrome (March 2023) (www.gov.uk).
Important: Formulation and dosage details
Formulation:
Solution for injection 1mg/8·5mL (Glypressin®) (s)
Dosage:
For variceal bleeding and hepatorenal syndrome off-label, by intravenous injection, 2mg followed by 1 or 2mg every 4 to 6 hours until bleeding is controlled, for up to 72 hours.